• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effect of drug combination of antitumor activity and myelotoxicity.

作者信息

Fujimoto S, Inouye T, Tsukagoshi S

出版信息

Gan. 1976 Apr;67(2):207-14.

PMID:964553
Abstract

Relationship between the survival time of L-1210-bearing mice and myelosuppression of normal mice after combination chemotherapy was studied. In a variety of combinations of 6-mercaptopurine, 6-thioguanine, and cyclophosphamide, a combination of cyclophosphamide and 6-thioguanine produced the highest increase in life span (ILS) and the highest number of 60-day survivors of all. In contrast, a combination of 6-mercaptopurine and 6-thioguanine showed as low as ILS as did single agents. A combination of 6-mercaptopurine, cyclophosphamide, and 6-thioguanine exhibited the second best effect on survival time of leukemic mice. However, in myelosuppression as measured by changes in the total number of nucleated cells, in the number of hematopoietic colony-forming cell, and in peroxidase level of femoral bone-marrow, the combination of 6-mercaptopurine and 6-thioguanine showed no more toxicity than the other 2-drug combinations. In addition to these findings, the presence of a striking difference in the cell number in ascitic fluid of leukemic mice among the animals given 6-thioguanine, and those given other 2- or 3-drug combinations may suggest that the difference in the antileukemic activity is not due to the difference in the toxicity against the host, but due to the difference in the activity of direct action of combined drugs on leukemic cells in the peritoneal cavity or in other sites.

摘要

相似文献

1
Effect of drug combination of antitumor activity and myelotoxicity.
Gan. 1976 Apr;67(2):207-14.
2
Combined effect of cytosine arabinoside and thiopurines.阿糖胞苷与硫嘌呤类的联合效应
Cancer Treat Rep. 1976 Dec;60(12):1925-34.
3
Potentiation of therapeutic effects of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride by 6-thioguanine in mouse tumor systems: comparison with other antimetabolites.
Gan. 1980 Feb;71(1):60-72.
4
Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.
Gan. 1977 Oct;68(5):543-52.
5
Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.小鼠L1210白血病观察到的耐药性基础:以不同组合给予甲氨蝶呤、6-硫鸟嘌呤、6-甲基巯基嘌呤核苷、6-巯基嘌呤、5-氟尿嘧啶和1-β-D-阿拉伯呋喃糖基胞嘧啶。
Cancer Res. 1981 Nov;41(11 Pt 1):4529-34.
6
Combined therapy of L1210 leukemia with Damvar and cytostatics.
Neoplasma. 1979;26(5):521-3.
7
Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
Cancer Treat Rep. 1976 Jan;60(1):23-7.
8
Scheduling of arabinosylcytosine and 6-thioguanine therapy.阿糖胞苷和6-硫鸟嘌呤疗法的给药安排。
Cancer Res. 1973 May;33(5):946-9.
9
Therapeutic synergism elicited by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride: synergistic cytocidal activity against L1210 cells in vitro.
Gan. 1980 Oct;71(5):659-66.
10
6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.6-巯基嘌呤增强伴刀豆球蛋白A结合的白血病细胞疫苗治疗的L1210荷瘤小鼠的主动免疫疗法。
Cancer Res. 1984 Feb;44(2):519-24.

引用本文的文献

1
Antitumor activity and toxicity of ACNU, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitroso urea hydrochloride, comparing two divided doses and a single dose.盐酸尼莫司汀(ACNU,3-[(4-氨基-2-甲基-5-嘧啶基)甲基]-1-(2-氯乙基)-1-亚硝基脲)的抗肿瘤活性和毒性:两剂分服与单剂服用的比较
Cancer Chemother Pharmacol. 1984;12(3):173-8. doi: 10.1007/BF00256540.